3Brooks A M, Thacker S M. Dapagliflozin for the treatment of type 2 diabetes [ J ]. Ann Pharmacother, 2009, 43 ( 7 ) : 1286. 被引量：1
4Monti JM, Monti D. The involvement of dopamine in the modulation of sleep and waking[J]. Sleep Med Rev, 2007, 11(2): 113. 被引量：1
5Cineotta A. Hypothalamic role in the insulin resistance syn- drome//[M]. Hansen B, Shaffrir E. Reistance and insulin resistance syndrome. London :Taylor & Francis, 2002: 271. 被引量：1
6Cineotta A H, Meier A H. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects [J]. Diabetes Care, 1996, 19(6): 667. 被引量：1
7Veroseienee. Cycloset Package Insert, 2009. FDA approved label. Available from: http://www, aeeessdata, fda. gov/ drugsatfda-docs/label/2009/O208661bl, pdf [ Last acce.ssed 23 September 2009 ]. 被引量：1
8Luo S, Ezrokhi M, Trubitsyna Y , et al. Intrahypothalamic circuitry regulating hypothalanlic fuel sensing to induce insulin sensitivity or insulin resistance [abstract] [] ]. Diabetologia, 2008, 51(Suppl l) :S59. 被引量：1
9Luo S, Luo J, Meier AH, et al. Dopaminergic neurotoxin administration to the area of the suprachiasmatie nuclei in- duces insulin resistance [J ]. Neuroreport, 1997, 8 ( 16 ) : 3495. 被引量：1
10Cincotta AH, Luo S, Zhang Y, et al. Chronic infusion of norepinephrine into the VMH of nomml rats induces the obese glucose-intolerant state[J]. AmJ Physiol Regul Inte- gr Comp Physiol, 2000, 278(2) :R435. 被引量：1
